Pharmacology Quiz: Inhaled Corticosteroids
20 questions · exam conditions
0:00
Inhaled CorticosteroidsQuestion 1 of 20

A 68-year-old female with severe COPD, a history of vertebral compression fracture, and recently diagnosed open-angle glaucoma is being managed. Due to frequent exacerbations (3 in the past year) and a blood eosinophil count of 400 cells/µL, her physician adds high-dose fluticasone furoate to her existing LAMA/LABA therapy.

Given the patient's comorbidities, which parameter requires the most vigilant monitoring following the initiation of the inhaled corticosteroid?

Bone mineral density.
Intraocular pressure.
Morning serum cortisol.
Oropharyngeal candidiasis.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Inhaled Corticosteroids

Practice Inhaled Corticosteroids in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Inhaled Corticosteroids, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 68-year-old female with severe COPD, a history of vertebral compression fracture, and recently diagnosed open-angle glaucoma is being managed. Due to frequent exacerbations (3 in the past year) and a blood eosinophil count of 400 cells/µL, her physician adds high-dose fluticasone furoate to her existing LAMA/LABA therapy.

Given the patient's comorbidities, which parameter requires the most vigilant monitoring following the initiation of the inhaled corticosteroid?

  1. Bone mineral density.
  2. Intraocular pressure. (correct answer)
  3. Morning serum cortisol.
  4. Oropharyngeal candidiasis.
Explanation: The correct answer is B. While all the options are potential side effects of high-dose inhaled corticosteroids (ICS), the patient's pre-existing glaucoma makes monitoring intraocular pressure (IOP) the most critical. Systemic absorption of ICS can increase IOP and worsen glaucoma. A is important long-term, but the patient already has an established fracture history, and changes in bone density occur slowly. C (adrenal suppression) is a risk, but less likely to cause acute complications than a significant rise in IOP in a patient with glaucoma. D is a common local side effect but is manageable and not as immediately threatening as worsening glaucoma.

Question 2

A patient's asthma therapy is being switched from fluticasone propionate HFA 110 mcg twice daily to ciclesonide HFA 80 mcg twice daily. The prescriber states these doses are approximately equivalent.

This dose equivalence is primarily explained by the fact that ciclesonide...

  1. is a prodrug that is activated to des-ciclesonide in the lungs, leading to higher local activity. (correct answer)
  2. has significantly lower plasma protein binding, allowing more free drug to reach target receptors.
  3. is formulated with a more efficient HFA propellant, resulting in greater lung deposition.
  4. possesses a much longer systemic half-life, allowing for accumulation in airway tissues.
Explanation: The correct answer is A. Ciclesonide is unique among inhaled corticosteroids because it is a prodrug. It is inhaled in an inactive form and is converted by esterases in the lungs to its active metabolite, des-ciclesonide, which has high glucocorticoid receptor affinity. This targeted activation in the lungs allows for high therapeutic effect at a lower nominal dose and potentially fewer local side effects in the oropharynx. B is incorrect; ciclesonide and its active metabolite have very high protein binding, which limits systemic effects. C is a property of the device, not the drug, and doesn't fully account for the potency difference. D is incorrect; a long systemic half-life is generally not a desirable property for minimizing systemic side effects.

Question 3

A 60-year-old patient with severe persistent asthma requires therapy with high-dose fluticasone propionate/salmeterol (500 mcg/50 mcg, two puffs twice daily). After a year on this regimen, they present with new-onset polyuria, polydipsia, and fatigue. Their asthma is well-controlled.

These new symptoms should prompt an evaluation for which potential systemic adverse effect of the patient's inhaled corticosteroid therapy?

  1. Hypokalemia
  2. Adrenal insufficiency
  3. Osteoporosis
  4. Hyperglycemia (correct answer)
Explanation: When evaluating systemic adverse effects from inhaled corticosteroids, you need to recognize that high-dose, long-term therapy can cause significant systemic absorption despite being "inhaled." The classic triad of polyuria, polydipsia, and fatigue should immediately make you think of hyperglycemia and potential steroid-induced diabetes. High-dose fluticasone propionate (500 mcg twice daily represents a very high dose) can achieve sufficient systemic levels to cause metabolic effects similar to oral corticosteroids. Corticosteroids increase blood glucose through multiple mechanisms: promoting gluconeogenesis, decreasing insulin sensitivity, and inhibiting glucose uptake by peripheral tissues. The patient's symptoms are textbook signs of hyperglycemia. Looking at the incorrect options: (A) Hypokalemia can occur with high-dose inhaled corticosteroids, but it doesn't typically present with this symptom triad - you'd expect muscle weakness or cardiac arrhythmias instead. (B) Adrenal insufficiency is a potential long-term risk with inhaled corticosteroids, but would present with fatigue, weakness, and hypotension rather than polyuria and polydipsia. (C) Osteoporosis is indeed a serious long-term complication of high-dose inhaled corticosteroids, but it's typically asymptomatic until fractures occur - it wouldn't cause these acute metabolic symptoms. Study tip: Remember the "3 P's" of hyperglycemia - polyuria, polydipsia, and polyphagia (though fatigue often substitutes for polyphagia in exam scenarios). High-dose inhaled corticosteroids can cause any systemic effect that oral steroids cause, just typically to a lesser degree.

Question 4

A 68-year-old female with severe COPD, a history of vertebral compression fracture, and recently diagnosed open-angle glaucoma is being managed. Due to frequent exacerbations (3 in the past year) and a blood eosinophil count of 400 cells/µL, her physician adds high-dose fluticasone furoate to her existing LAMA/LABA therapy.

Given the patient's comorbidities, which parameter requires the most vigilant monitoring following the initiation of the inhaled corticosteroid?

  1. Bone mineral density.
  2. Intraocular pressure. (correct answer)
  3. Morning serum cortisol.
  4. Oropharyngeal candidiasis.
Explanation: The correct answer is B. While all the options are potential side effects of high-dose inhaled corticosteroids (ICS), the patient's pre-existing glaucoma makes monitoring intraocular pressure (IOP) the most critical. Systemic absorption of ICS can increase IOP and worsen glaucoma. A is important long-term, but the patient already has an established fracture history, and changes in bone density occur slowly. C (adrenal suppression) is a risk, but less likely to cause acute complications than a significant rise in IOP in a patient with glaucoma. D is a common local side effect but is manageable and not as immediately threatening as worsening glaucoma.

Question 5

The parents of a 7-year-old child prescribed a fluticasone HFA MDI for asthma ask the pharmacist why a valved holding chamber (spacer) is necessary.

What is the most comprehensive explanation for the dual benefit of using a spacer with an MDI?

  1. It increases the total dose of drug released from the canister and slows inhalation.
  2. It eliminates the need to shake the inhaler and simplifies the timing of actuation.
  3. It reduces oropharyngeal drug deposition while increasing the fraction of the dose delivered to the lungs. (correct answer)
  4. It primarily prevents systemic side effects by trapping the medication within the chamber.
Explanation: The correct answer is C. Spacers provide two primary benefits. First, they slow down the aerosol particles and allow the propellant to evaporate, which reduces the amount of drug that impacts the back of the throat (oropharyngeal deposition). This reduces local side effects like thrush and dysphonia. Second, by reducing the particle velocity and the need for perfect hand-breath coordination, they increase the proportion of the inhaled dose that reaches the lower airways where it is needed. A is incorrect; spacers do not change the metered dose from the canister. B is incorrect; shaking is still required, and while coordination is made easier, it is not eliminated. D is partially true (reducing oropharyngeal deposition reduces swallowing and subsequent systemic absorption), but its main benefit is improving the therapeutic index by increasing lung deposition and decreasing local side effects.

Question 6

A 75-year-old patient with severe arthritis has difficulty coordinating pressing the canister and inhaling from her standard MDI. Her physician switches her to a breath-actuated MDI.

Which step of the standard MDI counseling is made unnecessary by the design of a breath-actuated MDI?

  1. Shaking the inhaler well before each use.
  2. Holding your breath for 10 seconds after inhalation.
  3. Inhaling slowly and deeply from the mouthpiece.
  4. Manually pressing the canister to release the medication. (correct answer)
Explanation: When evaluating inhaler devices, focus on understanding how each design addresses specific patient limitations and which counseling steps remain necessary versus which become automated. A breath-actuated MDI solves the coordination problem described in this scenario by automatically releasing medication when the patient inhales, eliminating the need for manual timing. The device contains a mechanism that triggers drug release in response to the patient's inspiratory flow, making option D correct – patients no longer need to manually press the canister while simultaneously inhaling. However, the other counseling steps remain essential. Option A is incorrect because shaking is still necessary to ensure proper drug suspension and uniform dosing, regardless of the actuation mechanism. Option B is wrong because the 10-second breath hold remains crucial for optimal drug deposition in the lungs – this step maximizes the time for particles to settle in the airways rather than being exhaled. Option C is incorrect because slow, deep inhalation is still required for effective drug delivery to the lower respiratory tract; the breath-actuated feature doesn't change optimal inhalation technique. The key distinction is that breath-actuated MDIs only eliminate the coordination challenge (pressing + inhaling simultaneously) while preserving all other best practices for effective drug delivery. Study tip: Remember that device modifications typically address one specific patient barrier while maintaining other essential steps. When analyzing inhaler questions, identify which single step the technology targets versus which fundamental drug delivery principles remain unchanged across all device types.

Question 7

A patient is prescribed a new ciclesonide HFA inhaler. The pharmacist provides counseling on its use.

The pharmacist should instruct the patient that priming the inhaler is necessary in which of the following situations?

  1. Immediately before each scheduled dose to ensure a full puff.
  2. Only after the actuator has been washed and is completely dry.
  3. Before the first use and again if the inhaler has not been used for more than one week. (correct answer)
  4. By shaking the inhaler vigorously and then inhaling without actuating the device.
Explanation: The correct answer is C. Priming an MDI involves releasing one or more sprays into the air to ensure the metering chamber is filled with the correct amount of drug and propellant. This is required before the very first use of the inhaler and also when the inhaler has not been used for a prolonged period (the exact duration varies by product but is typically 7-14 days). A is incorrect as priming before every dose is wasteful and unnecessary. B is incomplete; priming is needed at other times besides after cleaning. D describes an incorrect action; priming involves actuating the device away from the face.

Question 8

A patient with newly diagnosed moderate persistent asthma is prescribed a fluticasone propionate metered-dose inhaler (MDI) for twice-daily use. Two days later, the patient experiences an acute episode of wheezing and shortness of breath. They use their fluticasone MDI and report no improvement in symptoms after several minutes.

What is the most accurate pharmacological explanation for the lack of immediate relief?

  1. The patient likely performed the inhalation technique incorrectly, preventing drug delivery to the airways.
  2. Inhaled corticosteroids reduce airway hyperresponsiveness by targeting inflammation, a process with an onset of hours to days. (correct answer)
  3. Rapid tachyphylaxis to the bronchodilatory effects of fluticasone developed, rendering the dose ineffective.
  4. The prescribed dose was too low to saturate glucocorticoid receptors and overcome the acute bronchoconstriction.
Explanation: The correct answer is B. Inhaled corticosteroids (ICS) are controller medications that work by reducing underlying airway inflammation. This mechanism of action is not immediate; clinical effects on airway hyperresponsiveness and inflammation take hours to days to become apparent. They are not bronchodilators and are therefore not indicated for relief of acute symptoms. A is plausible, as poor technique is common, but it's not the primary pharmacological reason for the lack of effect in an acute setting. C is incorrect because ICS do not have bronchodilatory effects, so tachyphylaxis to this effect cannot occur. D is incorrect because the issue is the slow onset of the anti-inflammatory mechanism, not an insufficient dose for an acute effect which ICS do not possess.

Question 9

The parents of a 7-year-old child prescribed a fluticasone HFA MDI for asthma ask the pharmacist why a valved holding chamber (spacer) is necessary.

What is the most comprehensive explanation for the dual benefit of using a spacer with an MDI?

  1. It increases the total dose of drug released from the canister and slows inhalation.
  2. It eliminates the need to shake the inhaler and simplifies the timing of actuation.
  3. It reduces oropharyngeal drug deposition while increasing the fraction of the dose delivered to the lungs. (correct answer)
  4. It primarily prevents systemic side effects by trapping the medication within the chamber.
Explanation: The correct answer is C. Spacers provide two primary benefits. First, they slow down the aerosol particles and allow the propellant to evaporate, which reduces the amount of drug that impacts the back of the throat (oropharyngeal deposition). This reduces local side effects like thrush and dysphonia. Second, by reducing the particle velocity and the need for perfect hand-breath coordination, they increase the proportion of the inhaled dose that reaches the lower airways where it is needed. A is incorrect; spacers do not change the metered dose from the canister. B is incorrect; shaking is still required, and while coordination is made easier, it is not eliminated. D is partially true (reducing oropharyngeal deposition reduces swallowing and subsequent systemic absorption), but its main benefit is improving the therapeutic index by increasing lung deposition and decreasing local side effects.

Question 10

The parents of a 9-year-old child treated with a medium-dose inhaled corticosteroid for persistent asthma are concerned after reading online that the medication can stunt their child's growth.

Which statement most accurately characterizes the current understanding of the effect of inhaled corticosteroids on growth in children?

  1. A small, dose-dependent reduction in growth velocity is possible, primarily in the first year of therapy, but this effect does not typically impact final adult height. (correct answer)
  2. Any dose of an inhaled corticosteroid will lead to a clinically significant and permanent reduction in final adult height that outweighs the benefits of asthma control.
  3. The observed effects on growth are caused by the propellant used in MDI devices, not the corticosteroid itself, and can be avoided by using a DPI.
  4. Growth suppression is a theoretical concern that has been definitively disproven; any growth delay is attributable solely to poorly controlled asthma.
Explanation: The correct answer is A. Clinical evidence shows that inhaled corticosteroids, particularly at medium to high doses, can cause a small, transient reduction in growth velocity (on average, about 1 cm) during the first year of treatment. However, long-term studies indicate that this effect does not typically reduce the final predicted adult height. The benefit of controlling asthma, which itself can affect growth, far outweighs this small, non-permanent effect. B overstates the risk and is incorrect. C incorrectly attributes the effect to the propellant. D is also incorrect; while poorly controlled asthma can impact growth, a separate, small effect from the ICS has been demonstrated in clinical trials.

Question 11

A patient who uses a fluticasone furoate/vilanterol Ellipta inhaler once daily calls the pharmacy. They state the dose counter, which is now red, shows "02" and they do not have any refills remaining on their prescription.

What is the most appropriate advice for this patient?

  1. Continue using the inhaler for another week; there are several reserve doses after the counter reaches zero.
  2. Request a refill from the prescriber immediately, as the inhaler will lock out and become unusable after two more doses. (correct answer)
  3. The counter indicates you have two months of medication remaining, so no action is needed at this time.
  4. Shake the inhaler vigorously to see if you can aerosolize any of the remaining powder for the next few days.
Explanation: The correct answer is B. The dose counters on modern inhalers like the Ellipta are precise. When the counter turns red, it is a warning that the medication is running low. The number indicates the exact number of doses remaining. After the counter reaches '00', the device will lock, and no more doses can be actuated. Therefore, the patient needs to obtain a refill immediately. A is dangerous and incorrect advice for this device. C is a clear misinterpretation of the dose counter. D is incorrect as shaking will not provide additional doses from a locked device.

Question 12

When selecting an inhaled corticosteroid, a clinician aims to minimize the potential for systemic side effects, especially at higher doses. Which pharmacokinetic property is most desirable for achieving this goal?

  1. High oral bioavailability of the swallowed portion.
  2. Low degree of plasma protein binding.
  3. Extensive first-pass hepatic metabolism. (correct answer)
  4. Long systemic elimination half-life.
Explanation: The correct answer is C. A significant portion of any inhaled corticosteroid dose is swallowed. If this swallowed portion is subject to extensive first-pass metabolism in the liver, it is inactivated before it can reach systemic circulation, thus minimizing its contribution to systemic side effects. A is undesirable as high oral bioavailability would increase systemic exposure. B is undesirable because high protein binding sequesters the drug, leaving less free drug to exert systemic effects; therefore, low protein binding would increase systemic effects. D is undesirable as a longer half-life would prolong systemic exposure.

Question 13

A pharmacist is counseling a patient who is being switched from a fluticasone/salmeterol dry powder inhaler (DPI) to a budesonide/formoterol metered-dose inhaler (MDI). The patient has used the DPI for several years.

Which instruction represents the most critical change in inhalation technique for the new MDI device?

  1. Rinse your mouth with water and spit after each use to prevent thrush.
  2. Inhale as quickly and deeply as possible to ensure the medicine reaches your lungs.
  3. Begin to inhale slowly and deeply, then actuate the device while continuing to breathe in. (correct answer)
  4. Shake the inhaler vigorously for 30 seconds before each actuation to mix the medication.
Explanation: The correct answer is C. The most significant difference in technique between a DPI and an MDI is the required coordination and breathing pattern. MDIs require a slow, deep inhalation that is coordinated with the actuation of the device to ensure the aerosolized medication is carried deep into the lungs. In contrast, DPIs require a quick, forceful inhalation to de-aggregate the powder. A is important counseling for both device types containing an ICS, so it's not a change specific to the MDI. B describes the correct technique for a DPI, which is the most common error when switching to an MDI. D is an exaggeration; while shaking is necessary for MDI suspensions, the key skill change is the coordinated, slow inhalation.

Question 14

A patient with newly diagnosed moderate persistent asthma is prescribed a fluticasone propionate metered-dose inhaler (MDI) for twice-daily use. Two days later, the patient experiences an acute episode of wheezing and shortness of breath. They use their fluticasone MDI and report no improvement in symptoms after several minutes.

What is the most accurate pharmacological explanation for the lack of immediate relief?

  1. The patient likely performed the inhalation technique incorrectly, preventing drug delivery to the airways.
  2. Inhaled corticosteroids reduce airway hyperresponsiveness by targeting inflammation, a process with an onset of hours to days. (correct answer)
  3. Rapid tachyphylaxis to the bronchodilatory effects of fluticasone developed, rendering the dose ineffective.
  4. The prescribed dose was too low to saturate glucocorticoid receptors and overcome the acute bronchoconstriction.
Explanation: The correct answer is B. Inhaled corticosteroids (ICS) are controller medications that work by reducing underlying airway inflammation. This mechanism of action is not immediate; clinical effects on airway hyperresponsiveness and inflammation take hours to days to become apparent. They are not bronchodilators and are therefore not indicated for relief of acute symptoms. A is plausible, as poor technique is common, but it's not the primary pharmacological reason for the lack of effect in an acute setting. C is incorrect because ICS do not have bronchodilatory effects, so tachyphylaxis to this effect cannot occur. D is incorrect because the issue is the slow onset of the anti-inflammatory mechanism, not an insufficient dose for an acute effect which ICS do not possess.

Question 15

The use of an inhaled corticosteroid/formoterol combination inhaler for both daily maintenance and as-needed reliever therapy in persistent asthma (MART/SMART strategy) is based on which key pharmacological properties of the components?

  1. The rapid onset of budesonide provides immediate bronchodilation while the long duration of formoterol reduces inflammation.
  2. The long-acting beta-agonist provides rapid-onset bronchodilation for symptom relief, while the corticosteroid addresses the underlying inflammation with each use. (correct answer)
  3. Using a single inhaler improves patient adherence, which is the primary driver of improved outcomes with this strategy.
  4. The corticosteroid component upregulates beta-2 receptors, which prevents the development of tachyphylaxis to the reliever component.
Explanation: The correct answer is B. The MART/SMART strategy leverages the specific properties of formoterol, a long-acting beta-agonist (LABA) with a rapid onset of action comparable to albuterol, to provide immediate symptom relief. Each time the patient uses it for relief, they also receive a dose of the inhaled corticosteroid (ICS), which addresses the underlying inflammation that is driving the increased symptoms. A incorrectly reverses the roles of the two drugs. C describes a behavioral benefit (adherence) but not the core pharmacological principle. D describes a secondary synergistic mechanism but not the primary reason this combination is effective for both maintenance and relief.

Question 16

A 72-year-old male with severe COPD, a 50-pack-year smoking history, and a documented case of community-acquired pneumonia 18 months ago is experiencing frequent exacerbations. His physician is considering adding fluticasone propionate to his current LAMA/LABA regimen.

The addition of the inhaled corticosteroid component in this particular patient necessitates a careful risk-benefit discussion focusing on a well-established, increased risk of which adverse event?

  1. Paradoxical bronchospasm
  2. Pneumonia (correct answer)
  3. Pulmonary fibrosis
  4. QTc interval prolongation
Explanation: The correct answer is B. Multiple large clinical trials have demonstrated that the use of inhaled corticosteroids (ICS) in patients with COPD is associated with a statistically significant increased risk of pneumonia. This risk is particularly relevant in patients with risk factors such as advanced age, smoking history, and a prior history of pneumonia. A is a rare adverse effect of all inhalers, not specific to ICS in COPD. C is not associated with ICS use. D is a concern with other drug classes but not a primary concern for the ICS component.

Question 17

A patient with allergic asthma is well-controlled on a low-dose beclomethasone MDI. However, they continue to experience significant nasal congestion and rhinorrhea from seasonal allergies. The patient asks if taking an extra puff of their beclomethasone inhaler each day would help their nose feel better.

What is the most accurate response regarding the use of an inhaled corticosteroid for managing allergic rhinitis symptoms?

  1. Yes, increasing the dose will create a systemic anti-inflammatory effect that will effectively treat the rhinitis.
  2. No, the inhaled formulation is designed for local action in the lungs and has minimal impact on nasal inflammation. (correct answer)
  3. No, you should switch to a dry powder inhaler, as the powder formulation has better activity against rhinitis.
  4. Yes, but only if you also add a long-acting beta-agonist, as the combination is needed for nasal symptoms.
Explanation: The correct answer is B. Inhaled corticosteroids are designed for topical delivery to the lungs. While a small amount is absorbed systemically, the concentration is generally insufficient to treat inflammation in other parts of the body, like the nasal passages. The appropriate therapy would be an intranasal corticosteroid spray, which acts locally on the nasal mucosa. A is incorrect because while some systemic absorption occurs, relying on it to treat rhinitis is ineffective and unnecessarily increases the risk of side effects. C is incorrect as the delivery device does not change the drug's site of action. D is incorrect as LABAs are bronchodilators and have no role in treating allergic rhinitis.

Question 18

A 75-year-old patient with severe arthritis has difficulty coordinating pressing the canister and inhaling from her standard MDI. Her physician switches her to a breath-actuated MDI.

Which step of the standard MDI counseling is made unnecessary by the design of a breath-actuated MDI?

  1. Shaking the inhaler well before each use.
  2. Holding your breath for 10 seconds after inhalation.
  3. Inhaling slowly and deeply from the mouthpiece.
  4. Manually pressing the canister to release the medication. (correct answer)
Explanation: When evaluating inhaler devices, focus on understanding how each design addresses specific patient limitations and which counseling steps remain necessary versus which become automated. A breath-actuated MDI solves the coordination problem described in this scenario by automatically releasing medication when the patient inhales, eliminating the need for manual timing. The device contains a mechanism that triggers drug release in response to the patient's inspiratory flow, making option D correct – patients no longer need to manually press the canister while simultaneously inhaling. However, the other counseling steps remain essential. Option A is incorrect because shaking is still necessary to ensure proper drug suspension and uniform dosing, regardless of the actuation mechanism. Option B is wrong because the 10-second breath hold remains crucial for optimal drug deposition in the lungs – this step maximizes the time for particles to settle in the airways rather than being exhaled. Option C is incorrect because slow, deep inhalation is still required for effective drug delivery to the lower respiratory tract; the breath-actuated feature doesn't change optimal inhalation technique. The key distinction is that breath-actuated MDIs only eliminate the coordination challenge (pressing + inhaling simultaneously) while preserving all other best practices for effective drug delivery. Study tip: Remember that device modifications typically address one specific patient barrier while maintaining other essential steps. When analyzing inhaler questions, identify which single step the technology targets versus which fundamental drug delivery principles remain unchanged across all device types.

Question 19

A patient who uses a fluticasone furoate/vilanterol Ellipta inhaler once daily calls the pharmacy. They state the dose counter, which is now red, shows "02" and they do not have any refills remaining on their prescription.

What is the most appropriate advice for this patient?

  1. Continue using the inhaler for another week; there are several reserve doses after the counter reaches zero.
  2. Request a refill from the prescriber immediately, as the inhaler will lock out and become unusable after two more doses. (correct answer)
  3. The counter indicates you have two months of medication remaining, so no action is needed at this time.
  4. Shake the inhaler vigorously to see if you can aerosolize any of the remaining powder for the next few days.
Explanation: The correct answer is B. The dose counters on modern inhalers like the Ellipta are precise. When the counter turns red, it is a warning that the medication is running low. The number indicates the exact number of doses remaining. After the counter reaches '00', the device will lock, and no more doses can be actuated. Therefore, the patient needs to obtain a refill immediately. A is dangerous and incorrect advice for this device. C is a clear misinterpretation of the dose counter. D is incorrect as shaking will not provide additional doses from a locked device.

Question 20

A 60-year-old patient with severe persistent asthma requires therapy with high-dose fluticasone propionate/salmeterol (500 mcg/50 mcg, two puffs twice daily). After a year on this regimen, they present with new-onset polyuria, polydipsia, and fatigue. Their asthma is well-controlled.

These new symptoms should prompt an evaluation for which potential systemic adverse effect of the patient's inhaled corticosteroid therapy?

  1. Hypokalemia
  2. Adrenal insufficiency
  3. Osteoporosis
  4. Hyperglycemia (correct answer)
Explanation: When evaluating systemic adverse effects from inhaled corticosteroids, you need to recognize that high-dose, long-term therapy can cause significant systemic absorption despite being "inhaled." The classic triad of polyuria, polydipsia, and fatigue should immediately make you think of hyperglycemia and potential steroid-induced diabetes. High-dose fluticasone propionate (500 mcg twice daily represents a very high dose) can achieve sufficient systemic levels to cause metabolic effects similar to oral corticosteroids. Corticosteroids increase blood glucose through multiple mechanisms: promoting gluconeogenesis, decreasing insulin sensitivity, and inhibiting glucose uptake by peripheral tissues. The patient's symptoms are textbook signs of hyperglycemia. Looking at the incorrect options: (A) Hypokalemia can occur with high-dose inhaled corticosteroids, but it doesn't typically present with this symptom triad - you'd expect muscle weakness or cardiac arrhythmias instead. (B) Adrenal insufficiency is a potential long-term risk with inhaled corticosteroids, but would present with fatigue, weakness, and hypotension rather than polyuria and polydipsia. (C) Osteoporosis is indeed a serious long-term complication of high-dose inhaled corticosteroids, but it's typically asymptomatic until fractures occur - it wouldn't cause these acute metabolic symptoms. Study tip: Remember the "3 P's" of hyperglycemia - polyuria, polydipsia, and polyphagia (though fatigue often substitutes for polyphagia in exam scenarios). High-dose inhaled corticosteroids can cause any systemic effect that oral steroids cause, just typically to a lesser degree.